Related references
Note: Only part of the references are listed.Monoclonal Antibodies for the Treatment of Cancer
Joseph Thomas Pento
ANTICANCER RESEARCH (2017)
Pharmacokinetics of Monoclonal Antibodies
Josiah T. Ryman et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Role of interleukin-6 in cancer progression and therapeutic resistance
Neeraj Kumari et al.
TUMOR BIOLOGY (2016)
Interleukin-6 as a Therapeutic Target
Jean-Francois Rossi et al.
CLINICAL CANCER RESEARCH (2015)
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
Ingrid Ordas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics
Hazem E. El-Osta et al.
ONCOLOGIST (2011)
A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
J-F Rossi et al.
BRITISH JOURNAL OF CANCER (2010)
Pharmacokinetic and Pharmacodynamic Modeling of an Anti-Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma
Thomas Puchalski et al.
CLINICAL CANCER RESEARCH (2010)
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Adedigbo A. Fasanmade et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Share Paper
